1,2-苯并苊醌 | 6373-11-1

• 物质功能分类: 化学试剂 - 有机试剂 - 脂肪酮(含烯醇)
• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 中文名称: 1,2-苯并苊醌
• 中文别名: 醋蒽醌
• 英文名称: aceanthrenequinone
• 英文别名: aceanthrylene-1,2-dione；1,2-aceanthrenequinone；Aceanthrene-9,10-dione；1,2-Aceanthrylenedione
• CAS: 6373-11-1
• 化学式: C₁₆H₈O₂
• mdl: MFCD00013265
• 分子量: 232.238
• InChiKey: YAIBDWAANBTYIA-UHFFFAOYSA-N

物化性质

• 熔点：
  270-273 °C (lit.)
• 沸点：
  314.4°C (rough estimate)
• 密度：
  1.2260 (rough estimate)
• 稳定性/保质期：
  在常温常压下保持稳定，应避免与不相容的材料接触，并且要防止其与强氧化剂发生反应。

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37,S39
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2914190090
• 储存条件：
  密封储存于阴凉、干燥的库房，并常使用氮气进行保护。

SDS

Name:	Aceanthrenequinone 99+% Material Safety Data Sheet
Synonym:	1,2-Aceanthrylenedione
CAS:	6373-11-1

Section 1 - Chemical Product MSDS Name:Aceanthrenequinone 99+% Material Safety Data Sheet
Synonym:1,2-Aceanthrylenedione

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
6373-11-1	Aceanthrenequinone	99+ %	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
In case of fire, use water, dry chemical, chemical foam, or alcohol-resistant foam. Use agent most appropriate to extinguish fire.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 6373-11-1: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves and clothing to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize contact with skin.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: orange-brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 268.00 - 271.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C16H8O2
Molecular Weight: 232.24

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 6373-11-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Aceanthrenequinone - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 6373-11-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 6373-11-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 6373-11-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1,2-苯并苊醌 在 ammonium hydroxide 、 Oxone 作用下， 以 甲醇 、 水 为溶剂， 反应 60.0h， 生成 1,9-anthracenedicarboxylic imide
  参考文献：
  名称：

  新型杂化分子吡咯并苯二氮卓-蒽羧酰亚胺作为抗体-药物偶联物有效载荷的设计、合成和生物评价

  摘要：

  设计、合成了一系列结合吡咯并苯二氮卓 (PBD) 和蒽羧酰亚胺药效团的新型混合分子，并测试了其对各种癌细胞系的体外细胞毒性。该系列中最有效的化合物37b3表现出亚纳摩尔水平的细胞毒性，IC 50为 0.17–0.94 nM。37b3诱导 DNA 损伤并导致肿瘤细胞周期停滞和细胞凋亡。我们使用37b3作为有效载荷与曲妥珠单抗偶联以获得抗体-药物偶联物 (ADC) T-PBA。T-PBA保持了曲妥珠单抗的靶向模式和内化能力。我们证明了 T-PBA 可以通过溶酶体途径降解以释放有效载荷37b3内化后。T-PBA在体外对 Her2 阳性癌细胞显示出强大的杀伤作用。此外，T-PBA 显着抑制胃癌和卵巢癌异种移植小鼠模型中的肿瘤生长，而没有明显的毒性。总的来说，这些研究表明 T-PBA 代表了一种有前途的新 ADC，值得进一步研究。

  DOI：

  10.1021/acs.jmedchem.2c00471
• 作为产物：
  描述：

  草酰氯 、 蒽 在 aluminum (III) chloride 作用下， 以 二硫化碳 为溶剂， 反应 16.0h， 以75%的产率得到1,2-苯并苊醌
  参考文献：
  名称：

  新型杂化分子吡咯并苯二氮卓-蒽羧酰亚胺作为抗体-药物偶联物有效载荷的设计、合成和生物评价

  摘要：

  设计、合成了一系列结合吡咯并苯二氮卓 (PBD) 和蒽羧酰亚胺药效团的新型混合分子，并测试了其对各种癌细胞系的体外细胞毒性。该系列中最有效的化合物37b3表现出亚纳摩尔水平的细胞毒性，IC 50为 0.17–0.94 nM。37b3诱导 DNA 损伤并导致肿瘤细胞周期停滞和细胞凋亡。我们使用37b3作为有效载荷与曲妥珠单抗偶联以获得抗体-药物偶联物 (ADC) T-PBA。T-PBA保持了曲妥珠单抗的靶向模式和内化能力。我们证明了 T-PBA 可以通过溶酶体途径降解以释放有效载荷37b3内化后。T-PBA在体外对 Her2 阳性癌细胞显示出强大的杀伤作用。此外，T-PBA 显着抑制胃癌和卵巢癌异种移植小鼠模型中的肿瘤生长，而没有明显的毒性。总的来说，这些研究表明 T-PBA 代表了一种有前途的新 ADC，值得进一步研究。

  DOI：

  10.1021/acs.jmedchem.2c00471

文献信息

• Direct N–H/α,α,β,β-C(sp³)–H functionalization of piperidine<i>via</i>an azomethine ylide route: synthesis of spirooxindoles bearing 3-substituted oxindoles
  作者：Yanlong Du、Aimin Yu、Jiru Jia、Youquan Zhang、Xiangtai Meng

  DOI：10.1039/c6cc08996h

  日期：——

  A protocol for the direct functionalization of N-H/[small alpha],[small alpha],[small beta],[small beta]-C(sp3)-H of piperidine without any metal or external oxidants is reported. These reactions are promoted by 4-(trifluoromethyl)benzoic acid via an azomethine ylide intermediate....

  报道了在没有任何金属或外部氧化剂的情况下将哌啶的NH /小α，小α，小β，小β-C（sp 3）-H直接官能化的方案。这些反应是由4-（三氟甲基）苯甲酸通过甲亚胺叶立德中间体促进的。
• 波長変換のための高蛍光性光安定性発色団
  申请人：日東電工株式会社

  公开号：JP2016509621A

  公开（公告）日：2016-03-31

  本発明は、単一（ｉ＝０）または一連の（ｉ＝１、２など）の複素環式の系を含む高度に蛍光性の物質を提供する。この発色団は、可視光波長範囲および近赤外線波長範囲の光子の吸収および放射に特に有用である。光安定性で高度に発光性のこの発色団は種々の用途に、例えば波長変換膜に有用である。波長変換膜は、光起電力素子または太陽電池素子の太陽光の集光効率を有意に向上させる可能性を有する。

  This invention provides a highly fluorescent material containing a single (i=0) or a series of (i=1, 2, etc.) complex ring systems. This chromophore is particularly useful for the absorption and emission of photons in the visible light wavelength range and near-infrared wavelength range. This chromophore, highly luminescent with photostability, has various applications, such as in wavelength conversion films. Wavelength conversion films have the potential to significantly improve the concentration efficiency of solar light in photovoltaic devices or solar cells.
• Dermolipectomies Following Weight Loss after Surgery for Morbid Obesity
  作者：Leonidas Fotopoulos、Ioannis Kehagias、Fotis Kalfarentzos

  DOI：10.1381/096089200321593959

  日期：2000.10.1

  Background: Dermolipectomies play a major role in the functional and esthetic deformities which result from massive weight loss. Methods: From June 1994 to June 2000, 148 morbidly obese patients underwent various bariatric surgical procedures. After at least 1 year, 33 patients underwent 51 regional dermolipectomies performed by the same plastic surgeon. Results: All 33 patients underwent abdominal dermolipectomy. The average operative time was 194.2 min (110-420 min). The average amount of tissue excised was 2948.6 g (850-7525 g). 4 patients (12.1%) required blood transfusion. 6 patients (18.1%) developed complications, which included 1 case of post-operative bleeding, 3 wound infections and 2 skin dehiscences. Average length of hospital stay was 9.5 days (5-22 days). 15 of these patients (45.4%) simultaneously underwent abdominal incisional hernia repair; in 9 (24.2%), a Gore-Tex® mesh was used. In 2 patients the procedure was performed under emergency conditions due to small bowel obstruction. In 2 patients, simultaneous cholecystectomy was also performed. In 1 patient, a suction-assisted lipectomy of both thighs was necessary. 7 patients (21.2%) had mammaplasty, with average operative time 175.7 min (140-210 min). In 1 of them, breast implants were placed. There was no morbidity, and the average hospitalization was 6 days (4-9 days). Flankplasty was done in 4 patients (12.1%), thigh reduction plasty in 4 patients (12.1%), and arm reduction plasty in 3 patients (9%). The average operative time was 302.5 min (160-420), 246.2 min (230-280) and 203.3 min (180-240) respectively. Average tissue excised was 1503 g (725-2400 g), 1342.5 g (1050-1550 g), and 572.6 g (400-848 g), respectively. Morbidity was related to wound infection in 1 patient, and persistent edema of the left lower extremity in another. 4 of these 18 patients required blood transfusion. Average hospitalization was 8.2 days (6-11), 8 days (7-9) and 6 days (5-7) respectively. Conclusions: Regional dermolipectomies constitute the only available treatment for deformities following massive weight loss after bariatric surgery. Based on our experience, these procedures are safe, without serious complications and with good functional and esthetic results.

  背景：皮肤脂肪切除术在因大幅减重而导致的功能性和美学畸形中起着重要作用。方法：从1994年6月至2000年6月，148名重度肥胖患者接受了各种减肥手术。经过至少1年的观察，33名患者接受了由同一位整形外科医生施行的51例区域皮肤脂肪切除术。结果：所有33名患者均接受了腹部皮肤脂肪切除术。平均手术时间为194.2分钟（110-420分钟）。切除组织的平均重量为2948.6克（850-7525克）。4名患者（12.1%）需要输血。6名患者（18.1%）出现了并发症，包括1例术后出血，3例伤口感染和2例皮肤裂开。平均住院时间为9.5天（5-22天）。其中15名患者（45.4%）同时进行了腹部切口疝的修复；9例（24.2%）使用了Gore-Tex®网片。由于小肠梗阻，2名患者在紧急情况下进行手术。2名患者同时进行了胆囊切除术。在1名患者中，需要对双大腿进行吸引辅助脂肪切除术。7名患者（21.2%）进行了乳房整形，平均手术时间为175.7分钟（140-210分钟）。其中1名患者植入了乳房假体。没有出现病态情况，平均住院时间为6天（4-9天）。4名患者（12.1%）进行了侧腹成形术，4名患者（12.1%）进行了大腿缩小术，3名患者（9%）进行了手臂缩小术。平均手术时间分别为302.5分钟（160-420分钟），246.2分钟（230-280分钟）和203.3分钟（180-240分钟）。切除组织的平均重量分别为1503克（725-2400克），1342.5克（1050-1550克）和572.6克（400-848克）。1名患者因伤口感染出现病态，另一名患者因左下肢持续水肿出现病态。这18名患者中有4名需要输血。平均住院时间分别为8.2天（6-11天），8天（7-9天）和6天（5-7天）。结论：区域皮肤脂肪切除术是减肥手术后大幅减重导致畸形的唯一有效治疗方法。根据我们的经验，这些手术是安全的，没有严重并发症，并且具有良好的功能和美学效果。
• In situ generation of hydroperoxide by oxidation of benzhydrols to benzophenones using sodium hydride under oxygen atmosphere: use for the oxidative cleavage of cyclic 1,2-diketones to dicarboxylic acids
  作者：Sunhae Kang、Soyoung Lee、Minju Jeon、Sun Min Kim、Young Sug Kim、Hogyu Han、Jung Woon Yang

  DOI：10.1016/j.tetlet.2012.10.127

  日期：2013.1

  A facile oxidative cleavage of cyclic 1,2-diketones 1 to dicarboxylic acids 3 with hydroperoxide generated in situ has been developed. In situ generation of hydroperoxide was effected by the oxidation of 4,4′-dichlorobenzhydrol 2f to 4,4′-dichlorobenzophenone 4f using sodium hydride under oxygen atmosphere.

  已经开发了用现场产生的氢过氧化物容易地将环状1,2-二酮1氧化为二羧酸3的方法。通过在氧气气氛下使用氢化钠将4,4'-二氯苯甲酸2f氧化为4,4'-二氯二苯甲酮4f进行氢过氧化物的原位生成。
• Anthracene Carboxyimides and Their Dimers
  作者：Heinz Langhals、Gertrud Schönmann、Kurt Polborn

  DOI：10.1002/chem.200701844

  日期：2008.6.9

  Soluble anthracenedicarboxyimides have been prepared and undergo a photodimerisation of the anthracene skeleton, which is important for their application as antitumour agents, such as azonafides. Reaction under strongly alkaline conditions causes C-C coupling to form soluble dimeric fluorescent dyes with bathochromic absorption and fluorescence in the NIR region. These dyes are of special interest

  已经制备了可溶的蒽二甲酰亚胺并使其蒽骨架进行光二聚化，这对于它们作为抗肿瘤剂例如阿扎那非的应用是重要的。在强碱性条件下的反应导致CC偶合形成可溶的二聚体荧光染料，在NIR区域具有红移吸收和荧光。这些染料由于在较长波长下的吸收而特别受关注。